CAJ | 학술논문

目的检测胶质瘤患者脑脊液和血清中可溶性GPR56的水平并探讨其临床意义。方法应用酶联免疫吸附试验(ELISA)夹心法检测41例胶质瘤患者与31例脑外伤患者的脑脊液和血清GPR56水平，分析各组间GPR56表达差异。结果胶质瘤患者脑脊液GPR56水平(11.73±5.64)μgPL明显高于脑外伤患者(4.81±2.19)μgPL，P<0.01。垂体瘤患者GPR56水平(10.45±3.67)μgP L高于脑膜瘤(9.78±3.39)μgPL、神经鞘瘤(8.89±2.31)μgP L和听神经瘤(9.62±2.27)μgPL,P<0.05。胶质瘤患者血清GPR56水平(49.14±16.16)μgPL明显高于脑外伤患者(32.67±12.28)μgPL,P<0.01。垂体瘤患者GPR56水平(54.51±20.67)μgP L 高于脑膜瘤(36.78±13.39)μgPL、神经鞘瘤(42.79±12.31)μgPL和听神经瘤(44.62±12.27)μgPLP<0.05。结论胶质瘤患者脑脊液和血清中高水平的GPR56提示GPR56可能在胶质瘤的发生发展中有重要作用，可为胶质瘤的诊断和治疗提供一种新的靶位点。
목적검측효질류환자뇌척액화혈청중가용성GPR56적수평병탐토기림상의의。방법응용매련면역흡부시험(ELISA)협심법검측41례효질류환자여31례뇌외상환자적뇌척액화혈청GPR56수평，분석각조간GPR56표체차이。결과효질류환자뇌척액GPR56수평(11.73±5.64)μgPL명현고우뇌외상환자(4.81±2.19)μgPL，P<0.01。수체류환자GPR56수평(10.45±3.67)μgP L고우뇌막류(9.78±3.39)μgPL、신경초류(8.89±2.31)μgP L화은신경류(9.62±2.27)μgPL,P<0.05。효질류환자혈청GPR56수평(49.14±16.16)μgPL명현고우뇌외상환자(32.67±12.28)μgPL,P<0.01。수체류환자GPR56수평(54.51±20.67)μgP L 고우뇌막류(36.78±13.39)μgPL、신경초류(42.79±12.31)μgPL화은신경류(44.62±12.27)μgPLP<0.05。결론효질류환자뇌척액화혈청중고수평적GPR56제시GPR56가능재효질류적발생발전중유중요작용，가위효질류적진단화치료제공일충신적파위점。
Objective: To detect patients with glioma cerebrospinal fluid and serum soluble GPR56 level and its clinical applications. Methods: Through the methods of enzyme-linked immunosorbent assay (ELISA), we analyst the data on cerebrospinal fluid and serum to detect 41 patients with glioma and 31 patients with brain injury, to find the difference of GPR56 expression between the two groups. Results: Comparing with patients with brain injury(4.81± 2.19) μgP L, the GPR56 levels in the cerebrospinal fluid patients with glioma (11.73±5.64) μgP L. GPR56 levels of patients with pituitary tumors was (10.45±3.67) μgP L, which was higher than patients with meningiomas (9.78 ±3.39) μgP L, as well as the patients with schwannoma (8.89± 2.31)μgP L and acoustic neuroma (9.62 ±2.27)μgP L. The serum level of GPR56 in the group on patients with glioma was (49.14 ±16.16) μgP L, which was also significantly higher than patients with traumatic brain injury (32.67 ±12.28)μgP L. GPR56 level in group on patients with pituitary tumors (54.51 ±20.67)μgP L was higher than patients with meningiomas (36.78 ±13.39)μgP L, schwannoma (42.79± 12.31)μgP L and acoustic neuroma (44.62 ±12.27)μgP L. Conclusions: the high level of GPR56 in the cerebrospinal fluid and serum of patients with glioma prompt that GPR56 may have an important role in the occurrence and development of glioma and provide a new target for the clinical diagnosis and treatment.